Lixte Biotechnology Files 8-K
Ticker: LIXT · Form: 8-K · Filed: Aug 26, 2024 · CIK: 1335105
Sentiment: neutral
Topics: regulatory-filing, 8-K
Related Tickers: LIXT
TL;DR
LIXT filed an 8-K, but it's mostly boilerplate with no juicy details yet.
AI Summary
Lixte Biotechnology Holdings, Inc. filed an 8-K on August 26, 2024, reporting other events and financial statements. The company, incorporated in Delaware, is located at 680 East Colorado Boulevard, Suite 180, Pasadena, California. The filing does not contain specific financial figures or details about the 'other events'.
Why It Matters
This filing indicates that Lixte Biotechnology Holdings, Inc. has made a regulatory submission, but it lacks specific details on the nature of the events or financial information disclosed.
Risk Assessment
Risk Level: low — The filing is a standard 8-K with no immediate negative or positive financial implications disclosed.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Filer
- August 26, 2024 (date) — Date of Report
- 680 East Colorado Boulevard , Suite 180 Pasadena , California 91101 (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported by Lixte Biotechnology Holdings, Inc. in this 8-K filing?
The filing states 'Other Events' as an item information, but does not provide specific details within the provided text.
What is the nature of the 'Financial Statements and Exhibits' mentioned in the 8-K?
The filing lists 'Financial Statements and Exhibits' as an item information, but the specific content of these statements or exhibits is not detailed in the provided text.
When was Lixte Biotechnology Holdings, Inc. incorporated and in which jurisdiction?
Lixte Biotechnology Holdings, Inc. was incorporated in Delaware.
What is the principal executive office address for Lixte Biotechnology Holdings, Inc.?
The principal executive offices are located at 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101.
Does this 8-K filing contain any specific financial figures or material updates?
Based on the provided text, this 8-K filing does not contain specific financial figures or material updates beyond listing the report items.
Filing Stats: 379 words · 2 min read · ~1 pages · Grade level 12.1 · Accepted 2024-08-26 16:05:14
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-24-033870.txt ( ) — 270KB
- lixt-20240826.xsd (EX-101.SCH) — 3KB
- lixt-20240826_def.xml (EX-101.DEF) — 26KB
- lixt-20240826_lab.xml (EX-101.LAB) — 36KB
- lixt-20240826_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 26, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Registrant) By: /s/ BASTIAAN VAN DER BAAN Bastiaan van der Baan Chief Executive Officer INDEX TO EXHIBITS Exhibit No. Description 99.1 Press release announcing the dosing of the first patient with LB-100 in a clinical trial for the treatment of unresponsive (MSI Low) metastatic colorectal cancer. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)